OBM
原創生醫股份有限公司
OBM is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is OBM-B01 (Phase 1 trial authorized, Cyanide poisoning), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| OBM-B01 | — | Phase 1 trial authorized | Cyanide poisoning | Taiwan | 2026-08-03 | Company disclosure |
| OBM-A01 | — | — | — | — | 2024-05-31 | Company disclosure |
| OBM-CL | — | — | — | — | 2024-05-31 | Company disclosure |
Key events
- OBM-B01: Phase 1 trial authorized
Related Drugnews articles
No related articles in this language.